Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats

American Journal of Pathology

Volumn 181, Issue 2, 2012, Pages 472-477

  Kolosova, Nataliya G ^a   Muraleva, Natalia A ^a   Zhdankina, Anna A ^b   Stefanova, Natalia A ^a   Fursova, Anzhela Z ^a   Blagosklonny, Mikhail V ^c  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HETEROGENEITY; CELL NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GLIA CELL; HISTOPATHOLOGY; INCIDENCE; MALE; NONHUMAN; PHOTORECEPTOR CELL; PRIORITY JOURNAL; RAT; RETINA MACULA AGE RELATED DEGENERATION; SENESCENCE; WISTAR RAT;

ANIMALS; CHOROID; MACULAR DEGENERATION; MICE; NERVE DEGENERATION; PHOSPHORYLATION; RATS; RATS, WISTAR; RETINAL PIGMENT EPITHELIUM; RIBOSOMAL PROTEIN S6; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84864128574     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.04.018     Document Type: Article

References (57)

1. A.C. Bird Therapeutic targets in age-related macular disease J Clin Invest 120 2010 3033 3041
2. L.P. Aiello, E.A. Pierce, E.D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G.L. King, L.E. Smith Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF receptor chimeric proteins Proc Natl Acad Sci U S A 92 1995 10457 10461
3. H. Ozaki, M.S. Seo, K. Ozaki, H. Yamada, E. Yamada, N. Okamoto, F. Hofmann, J.M. Wood, P.A. Campochiaro Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization Am J Pathol 156 2000 697 707
4. V. Poulaki, W. Qin, A.M. Joussen, P. Hurlbut, S.J. Wiegand, J. Rudge, G.D. Yancopoulos, A.P. Adamis Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF J Clin Invest 109 2002 805 815
5. T. Yoshida, K. Ohno-Matsui, S. Ichinose, T. Sato, N. Iwata, T.C. Saido, T. Hisatomi, M. Mochizuki, I. Morita The potential role of amyloid beta in the pathogenesis of age-related macular degeneration J Clin Invest 115 2005 2793 2800
6. R. Rosenthal, H. Wohlleben, G. Malek, L. Schlichting, H. Thieme, C. Bowes Rickman, O. Strauss Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration Biochem Biophys Res Commun 323 2004 1203 1208
7. D.P. Stiehl, W. Jelkmann, R.H. Wenger, T. Hellwig-Burgel Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway FEBS Lett 512 2002 157 162
8. D.P. Stiehl, R. Wirthner, J. Koditz, P. Spielmann, G. Camenisch, R.H. Wenger Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels: evidence for an autoregulatory oxygen-sensing system J Biol Chem 281 2006 23482 23491
9. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, G.L. Semenza, E. Van Obberghen Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway J Biol Chem 277 2002 27975 27981
10. C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M.N. Monthouel-Kartmann, E. Van Obberghen Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I Mol Endocrinol 19 2005 1304 1317
11. V. Poulaki, A.M. Joussen, N. Mitsiades, C.S. Mitsiades, E.F. Iliaki, A.P. Adamis Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy Am J Pathol 165 2004 457 469
12. M.G. Slomiany, S.A. Rosenzweig IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407 Invest Ophthalmol Vis Sci 45 2004 2838 2847
13. M.G. Slomiany, S.A. Rosenzweig Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19 Am J Physiol Cell Physiol 287 2004 C746 C753
14. M.G. Slomiany, S.A. Rosenzweig Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion J Pharmacol Exp Ther 318 2006 666 675
15. Z.N. Demidenko, M.V. Blagosklonny The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1alpha Cell Cycle 10 2011 1557 1562
16. A. Stahl, L. Paschek, G. Martin, N.J. Gross, N. Feltgen, L.L. Hansen, H.T. Agostini Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro FEBS Lett 582 2008 3097 3102
17. R.B. Nussenblatt, G. Byrnes, H.N. Sen, S. Yeh, L. Faia, C. Meyerle, K. Wroblewski, Z. Li, B. Liu, E. Chew, P.R. Sherry, P. Friedman, F. Gill, F. Ferris 3rd A randomized pilot study of systemic immunosuppression in the treatment of age related macular degeneration with choroidal neovascularization Retina 30 2010 1579 1587
18. C. Zhao, D. Yasumura, X. Li, M. Matthes, M. Lloyd, G. Nielsen, K. Ahern, M. Snyder, D. Bok, J.L. Dunaief, M.M. LaVail, D. Vollrath mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice J Clin Invest 121 2011 369 383
19. M.V. Blagosklonny Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition Cell Cycle 5 2006 2087 2102
20. M.V. Blagosklonny An anti-aging drug today: from senescence-promoting genes to anti-aging pill Drug Disc Today 12 2007 218 224
21. Z.N. Demidenko, S.G. Zubova, E.I. Bukreeva, V.A. Pospelov, T.V. Pospelova, M.V. Blagosklonny Rapamycin decelerates cellular senescence Cell Cycle 8 2009 1888 1895
22. O.V. Leontieva, M.V. Blagosklonny DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence Aging (Albany NY) 2 2010 924 935
23. T. Vellai, K. Takacs-Vellai, Y. Zhang, A.L. Kovacs, L. Orosz, F. Muller Genetics: influence of TOR kinase on lifespan in C. elegans Nature 426 2003 620
24. P. Kapahi, B.M. Zid, T. Harper, D. Koslover, V. Sapin, S. Benzer Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway Curr Biol 14 2004 885 890
25. S.D. Katewa, P. Kapahi Role of TOR signaling in aging and related biological processes in Drosophila melanogaster Exp Gerontol 46 2011 382 390
26. D.E. Harrison, R. Strong, Z.D. Sharp, J.F. Nelson, C.M. Astle, K. Flurkey, N.L. Nadon, J.E. Wilkinson, K. Frenkel, C.S. Carter, M. Pahor, M.A. Javors, E. Fernandezr, R.A. Miller Rapamycin fed late in life extends lifespan in genetically heterogenous mice Nature 460 2009 392 396
27. R.A. Miller, D.E. Harrison, C.M. Astle, J.A. Baur, A.R. Boyd, R. DE Cabo, E. Fernandez, K. Flurkey, M.A. Javors, J.F. Nelson, C.J. Orihuela, S. Pletcher, Z.D. Sharp, D. Sinclair, J.W. Starnes, J.E. Wilkinson, N.L. Nadon, R. Strong Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice J Gerontol A Biol Sci Med Sci 66 2011 191 201
28. V.N. Anisimov, M.A. Zabezhinski, I.G. Popovich, T.S. Piskunova, A.V. Semenchenko, M.L. Tyndyk, M.N. Yurova, M.V. Blagosklonny Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice Cell Cycle 10 2011 4230 4236
29. M.V. Blagosklonny Validation of anti-aging drugs by treating age-related diseases Aging (Albany NY) 1 2009 281 288
30. A.A. Zhdankina, A. Fursova, S.V. Logvinov, N.G. Kolosova Clinical and morphological characteristics of chorioretinal degeneration in early aging OXYS rats Bull Exp Biol Med 146 2008 455 458
31. V.B. Saprunova, D.I. Pilipenko, A.V. Alexeevsky, A. Fursova, N.G. Kolosova, L.E. Bakeeva Lipofuscin granule dynamics during development of age-related macular degeneration Biochemistry (Mosc) 75 2010 130 138
32. A.M. Markovets, V.B. Saprunova, A.A. Zhdankina, A. Fursova, L.E. Bakeeva, N.G. Kolosova Alterations of retinal pigment epithelium cause AMD-like retinopathy in senescence-accelerated OXYS rats Aging (Albany NY) 3 2011 44 54
33. A.M. Markovets, A.Z. Fursova, N.G. Kolosova Therapeutic action of the mitochondria-targeted antioxidant SkQ1 on retinopathy in OXYS rats linked with improvement of VEGF and PEDF gene expression PLoS One 6 2011 e21682
34. N.A. Stefanova, A. Fursova, K.N. Sarsenbaev, N.G. Kolosova Effects of Cistanche deserticola on behavior and signs of cataract and retinopathy in senescence-accelerated OXYS rats J Ethnopharmacol 138 2011 624 632
35. E.E. Korbolina, O.S. Kozhevnikova, N.A. Stefanova, N.G. Kolosova Quantitative trait loci on chromosome 1 for cataract and AMD-like retinopathy in senescence-accelerated OXYS rats Aging (Albany NY) 4 2012 49 59
36. Age-Related Eye Disease Research Group The Age-Related Eye Disease Study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: AREDS report No. 6 Am J Ophthalmol 132 2001 668 681
37. K.L. Jin, X.O. Mao, D.A. Greenberg Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia Proc Natl Acad Sci U S A 97 2000 10242 10247
38. K. Nishijima, Y.S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S.J. Samuelsson, G.S. Robinson, A.P. Adamis, D.T. Shima Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 2007 53 67
39. M. Saint-Geniez, A.S. Maharaj, T.E. Walshe, B.A. Tucker, E. Sekiyama, T. Kurihara, D.C. Darland, M.J. Young, P.A. D'Amore Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors PLoS One 3 2008 e3554
40. N.S. Dejneka, A.M. Kuroki, J. Fosnot, W. Tang, M.J. Tolentino, J. Bennett Systemic rapamycin inhibits retinal and choroidal neovascularization in mice Mol Vis 10 2004 964 972
41. L.Y. Leung, H.K. Lim, M.W. Abell, J.J. Zimmerman Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose Drug Monit 28 2006 51 61
42. M. Krebs, B. Brunmair, A. Brehm, M. Artwohl, J. Szendroedi, P. Nowotny, E. Roth, C. Fürnsinn, M. Promintzer, C. Anderwald, M. Bischof, M. Roden The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man Diabetes 56 2007 1600 1607
43. M. Veroux, D. Corona, P. Veroux Pregnancy under everolimus-based immunosuppression Transpl Int 24 2011 e115 e117
44. P. Major Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex Aging (Albany NY) 3 2011 189 191
45. K. Araki, A.P. Turner, V.O. Shaffer, S. Gangappa, S.A. Keller, M.F. Bachmann, C.P. Larsen, R. Ahmed mTOR regulates memory CD8 T-cell differentiation Nature 460 2009 108 112
46. C. Chen, Y. Liu, P. Zheng mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells Sci Signal 2 2009 ra75
47. M.V. Blagosklonny Rapamycin-induced glucose intolerance: hunger or starvation diabetes Cell Cycle 10 2011 4217 4224
48. H.M. Kauffman, W.S. Cherikh, Y. Cheng, D.W. Hanto, B.D. Kahan Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883 889
49. J.M. Campistol, J. Eris, R. Oberbauer, P. Friend, B. Hutchison, J.M. Morales, K. Claesson, G. Stallone, G. Russ, L. Rostaing, H. Kreis, J.T. Burke, Y. Brault, J.A. Scarola, J.F. Neylan Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581 589
50. G. Stallone, A. Schena, B. Infante, S. Di Paolo, A. Loverre, G. Maggio, E. Ranieri, L. Gesualdo, F.P. Schena, G. Grandaliano Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317 1323
51. M.V. Blagosklonny Prevention of cancer by inhibiting aging Cancer Biol Ther 7 2008 1520 1524
52. K. Inoki, M.N. Corradetti, K.L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 2005 19 24
53. C.K. Tsang, H. Qi, L.F. Liu, X.F.S. Zheng Targeting mammalian target of rapamycin (mTOR) for health and diseases Drug Disc Today 12 2007 112 124
54. M.V. Blagosklonny, M.N. Hall Growth and aging: a common molecular mechanism Aging (Albany NY) 1 2009 357 362
55. R. Zoncu, A. Efeyan, D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
56. V.N. Anisimov, M.A. Zabezhinski, I.G. Popovich, T.S. Piskunova, A.V. Semenchenko, M.L. Tyndyk, M.N. Yurova, M.P. Antoch, M.V. Blagosklonny Rapamycin extends maximal lifespan in cancer-prone mice Am J Pathol 176 2010 2092 2097
57. F. Nicoletti, P. Fagone, P. Meroni, J. McCubrey, K. Bendtzen mTOR as a multifunctional therapeutic target in HIV infection Drug Discov Today 16 2011 715 721